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ICAM-1 = intercellular adhesion molecule-1; MPI = minimal persistent inflammation.
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Introduction
The overall view of the pathophysiology of respiratory
allergy has changed profoundly over the past 10 years.
Increasing attention has been devoted to the relationship
between rhinitis and asthma (i.e. between the upper and
the lower respiratory airways) that was first noted in epi-
demiological studies. In addition, clinical observations
provide compelling evidence for the following phenomena:
the frequent co-existence of rhinitis and asthma, rhinitis as
a risk factor for developing asthma, the occurrence of
bronchial hyperresponsiveness in rhinitis, the association
between upper respiratory infections and asthma exacerba-
tions, the existence of a common pathogenic mechanisms
between rhinitis and asthma, and the exacerbating role of
sinusitis in asthma. More detailed knowledge of the mecha-
nisms of inflammation (e.g. antigen presentation, cytokines,
chemokines and adhesion molecules) has clarified, at least
in part, the functional relationships between the nose and
bronchi. It is therefore reasonable to consider respiratory
allergy as a disorder of the whole respiratory tract, which is
manifest clinically as rhinitis and/or asthma, rather than as
distinct diseases confined to specific organs. Conse-
quently, some new terms have been introduced, including
‘allergic rhinobronchitis’, ‘one airway one disease’, and
‘united airways disease’ [1]. This approach of considering
respiratory allergy as a disorder of the whole respiratory
tract has relevant therapeutic implications because treating
diseases of the upper airways can impact the lower
airways, and drugs affecting the common pathogenic
mechanisms can act on both compartments.
Functional and immunological aspects
The association between the upper and lower respiratory
airways has been confirmed by numerous epidemiological
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studies. Although the studies have some methodological
limits, the data from the literature are quite consistent.
Several cross-sectional trials have shown that the coexis-
tence of rhinitis and asthma is extremely common: when a
sufficiently detailed methodology is used, rhinitis is detected
in more than 90% of asthmatic subjects [2]. Longitudinal
studies have shown that subjects with rhinitis are more likely
to develop asthma, and that rhinitis usually precedes
asthma (see [3,4] for a review). This latter phenomenon also
occurs in non-allergic rhinitis, as demonstrated in recent
trials; Leynaert et al showed that rhinitis itself is a risk factor
for developing asthma, even in non-atopic subjects [5].
The relationship between the nose and bronchi has been
studied from several viewpoints, each elucidating a differ-
ent aspect of the mechanism. In allergic subjects, allergen-
specific nasal challenge can elicit both an immediate
bronchoconstrictor response and an increase in airway
responsiveness [6,7], as well as a bronchial inflammation,
characterized by an influx of eosinophils [8]. Segmental
bronchial challenge can also induce nasal symptoms, as
well as nasal inflammation in patients with allergic rhinitis
[9]. The inflammatory process is central to the allergic
response [10], as clearly demonstrated by several experi-
mental models including nasal and bronchial challenge
[11]. When an allergic reaction takes place (i.e.
allergen–IgE-mast cell), the so-called early phase occurs
within minutes. This first step involves the release of hista-
mine, vasodilation, increased permeability, and bron-
choconstriction. This early phase is followed by a complex
network of inflammatory phenomena in which T lympho-
cytes, cytokines and adhesion molecules are involved.
During the early phase, specific adhesion molecules are
expressed ex novo or upregulated on the surface of the
endothelium (selectins) and the epithelium (integrins). The
adhesion molecules favour the rolling, extravasation, and
migration towards the epithelium of inflammatory cells. The
kinetics of inflammation following allergen exposure
involve the migration of inflammatory cells to the mucosa
within about 30 min. Inflammatory infiltration increases
over the following 24 hours and then slowly subsides.
Using induced sputum, Polosa et al [12] showed that sub-
jects with rhinitis alone have an increased number of
eosinophils during the grass pollen season. Crimi et al
[13] recently compared the bronchial inflammatory
response following allergen-specific challenge in patients
suffering from asthma alone or rhinitis alone. Utilizing
bronchial biopsy and lavage, the authors found no mor-
phological difference between the two groups: the
bronchial inflammatory response (cell influx and basement
membrane thickening) is the same regardless of which
airway is affected by disease (Fig. 1), confirming that
atopic subjects have a common inflammatory response.
When exposure to allergen is too low to provoke symp-
toms, a weak inflammatory infiltration occurs in the
mucosa. This process is called ‘minimal persistent inflam-
mation’ (MPI) and it has been demonstrated in both mite-
induced and pollen-induced rhinitis [14]. MPI also involves
Figure 1
Bronchial biopsies obtained after allergen-specific bronchial challenge in an asthmatic subject (left) and in a rhinitic subject (right). 
The inflammatory responses are superimposable in the two subjects [20].Respiratory Research    Vol 2 No 6 Passalacqua and Canonica
a weak and persistent expression of intercellular adhesion
molecule-1 (ICAM-1), the major receptor molecule for
human rhinoviruses. MPI and ICAM-1 expression in
asymptomatic allergic subjects are important because
asthma exacerbations in children are frequently related to
upper respiratory viral infections [15], primarily due to
rhinoviruses. Another functional systemic link between the
nose and bronchi has recently been hypothesized, based
on the observation that bone marrow can promptly and
specifically respond to nasal challenge by increasing the
rates of production and maturation of eosinophilic precur-
sors [16] (Fig. 2).
Indeed, the association of rhinitis and asthma has also
been observed in non-atopic subjects [5], in whom mech-
anisms other than allergic inflammation must be operative.
The upper respiratory tract functions as a physical filter,
resonator, heat exchanger, and humidifier of inhaled air.
Failure of any of these functions could clearly alter the
homeostasis of the lower respiratory airway tract [17].
When asthmatics orally hyperventilate with cold air, they
suffer a decrease in forced expiratory volume, whereas
their nasal resistance is increased [18].
Therapeutic aspects
The connection between the upper and lower respiratory
tracts can also be studied in terms of response to therapy.
If we consider the functional link (inflammation in particu-
lar) existing between the nose and the bronchi, it is rea-
sonable to expect that effective treatment of rhinitis may
have some effect on the bronchi [1]. In this sense, the
anatomical difference between the two compartments
must be taken into account: nose and paranasal sinuses
are rigid boxes where erectile sinusoids predominate,
whereas bronchi are included in elastic parenchyma and
are rich in smooth muscle tissue. In fact, β2 agonists are
highly effective against asthma but have no effect on rhini-
tis; conversely, H1 receptor antagonists treat rhinitis
symptoms but are ineffective against asthma.
The use of intranasal corticosteroids significantly reduced
concomitant bronchial hyperresponsiveness as well as
asthma symptoms in asthmatic patients in several clinical
trials (for a review see [19]). The same result was observed
in patients with allergic rhinitis, where cetirizine significantly
reduced non-specific bronchial hyperresponsiveness [20].
This synergistic effect was also demonstrated in patients
with rhinitis and asthma, using a H1 receptor antagonist in
association with a leukotriene receptor antagonist [21].
The link between upper respiratory disease and asthma is
also evident in children, where allergic inflammation and
viral infections seem to interact. The bronchodilator action
of H1 receptor antagonists per se is weak and of negligi-
ble clinical relevance. The effect on the lower airways, pre-
viously demonstrated with ketotifen [22] and recently
demonstrated with some new compounds, seems to be
due to their anti-allergic properties [23]. Continuous treat-
ment for 1 year with terfenadine (versus placebo) reduced
the occurrence of upper respiratory infections as well as
nasal symptoms and local inflammation by approximately
50% [24]. Cetirizine treatment for six consecutive months
similarly resulted in a significant global reduction of the
need for asthma medications [25]. These observations,
derived from small groups, have recently been confirmed
by the large Early Treatment of Atopic Child study: early
and continuous anti-histamine treatment reduces the sub-
sequent onset of asthma in atopic children [26].
Conclusion
It is now recognized that allergic rhinitis and asthma are
two clinical manifestations of a single disorder of the
airways. This view is supported by numerous epidemiolog-
ical, clinical and immunological observations suggesting
that allergy is a systemic disorder of the respiratory tract.
Indeed, rhinitis and asthma share common pathogenetic
mechanisms, a high prevalence in the population, negative
effects on the quality of life, and certain therapeutic
approaches. The strength of the considerations mentioned
prompted the World Health Organization to publish an
extensive position paper devoted to the relationship
between rhinitis and asthma and its therapeutic implications
[27], highlighting the concept of ‘one airway one disease’.
Inflammation represents the most important link between
the upper and lower respiratory tracts, as confirmed by the
measurable effects of drug therapy. Obviously, some ques-
tions remain unanswered: in particular, the relative weight
and role of allergy as compared with other possible mecha-
nisms that are involved, for instance, in non-atopic subjects.
Figure 2
Some of the possible functional interactions between the nose and
bronchi, in which the inflammatory process plays a central role (see text).The united airways disease hypothesis is clearly sup-
ported by the data, and new therapeutic rationales in the
management of respiratory allergy must be put forward.
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